Fecal Microbiota Transplant (FMT)

C. difficile Infection (Gold Standard)#

FMT cures recurrent C. difficile in ~90% of cases—far superior to antibiotics alone. FDA-approved live biotherapeutic products (REBYOTA, VOWST) now available. Mechanism primarily through restored colonization resistance and secondary bile acid metabolism.

IBD (Mixed Results)#

Ulcerative colitis: Multiple RCTs show induction of remission in 25-35% of patients (vs. 5-10% placebo), but durability and optimal protocols remain uncertain. Crohn's disease: Preliminary evidence; timing of repeat FMT may be critical (e.g., second FMT within 3 weeks showed greater mucosal improvement).

Challenge: IBD involves immune dysregulation beyond what microbiome restoration alone can correct.

Multiple Sclerosis (Pilot Data)#

Mouse models: FMT from MS-twin-derived microbiota increased autoimmune incidence; FMT from healthy donors showed protective immunoregulatory activity.^{[1]Gut-oriented interventions in patients with multiple sclerosis: fact or fiction?V. Martinelli, M. Albanese, M. Altieri et al. · 2022Open reference 1 ↓} Sutterella reduction identified as a key change in MS-associated FMT. Human data remain very limited; larger trials needed.

Cardiovascular Disease / Hypertension#

FMT from atherosclerotic mice induces atherosclerosis in recipient mice, demonstrating causal microbial contribution.^{[2]Microbiome and Cardiovascular DiseaseHilde Herrema, Max Nieuwdorp, Albert K. Groen · 2020Open reference 2 ↓} FMT as an innovative therapeutic approach for managing CVD is under active investigation.^{[3]Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorderAmeer Luqman, Adil Hassan, Mehtab Ullah et al. · 2024Open reference 3 ↓}

Autism Spectrum Disorder (Open-Label)#

Open-label FMT trial in ASD children reduced levels of p-cresol, 4-hydroxyphenylacetate, and indole; modified Prevotella, Bifidobacterium, and Desulfovibrio abundances.^{[4]Zheng 2021 -- The Role of Bacterial-Derived Aromatic Amino Acids Metabolites Relevant in Autism Spectrum Disorders: A Comprehensive ReviewYuanpeng Zheng, Marie K. Bek, Naika Z. Prince et al. · 2021Open reference 4 ↓}

GI symptoms and behavioral measures improved; effects persisted at 2-year follow-up in extended observations. Controlled trials are needed to confirm efficacy.

Other Applications Under Investigation#

Metabolic syndrome/obesity: FMT from lean donors to obese recipients temporarily improved insulin sensitivity in some trials. Hepatic encephalopathy: FMT reduced hospitalizations in cirrhotic patients. Graft-versus-host disease: FMT showing promise for steroid-refractory GI GVHD.

Metal Angle#

FMT may restore the metal-handling capacity of the microbiome disrupted by heavy metal exposure.

Biosorption capacity: Healthy donor microbiota includes metal-binding species (Lactobacillus, Bifidobacterium) that sequester lead (Pb), cadmium (Cd), and mercury (Hg) in the gut lumen. Barrier repair: Restored SCFA production reduces paracellular metal absorption through healed tight junctions. Competitive exclusion: Donor commensals displace metal-tolerant pathobionts (Enterobacteriaceae) that thrive in metal-contaminated, inflamed environments.

Detoxification enzymes: Donor bacteria may contribute arsenic methyltransferases (arsM), mercury demethylases (merB), and other biotransformation enzymes.

Limitations and Risks#

Donor screening: Risk of transmitting infections, antibiotic-resistant organisms, or unfavorable metabolic phenotypes. Durability: Engraftment is often incomplete; recipient diet and environment may select against donor species. Standardization: No consensus on preparation (fresh vs. frozen, capsule vs. colonoscopy), dosing, or donor selection criteria.

Regulatory: Classified as a biological product; access varies by jurisdiction.